Icecure Net Receivables from 2010 to 2026

ICCM Stock  USD 0.57  0.02  3.39%   
Icecure Medical Net Receivables yearly trend continues to be very stable with very little volatility. Net Receivables is likely to drop to about 194.2 K. During the period from 2010 to 2026, Icecure Medical Net Receivables quarterly data regression pattern had sample variance of 40.5 B and median of  65,772. View All Fundamentals
 
Net Receivables  
First Reported
2012-09-30
Previous Quarter
1.3 M
Current Value
104 K
Quarterly Volatility
564.2 K
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Icecure Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Icecure Medical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 400.9 K, Interest Expense of 164.3 K or Selling General Administrative of 10.8 M, as well as many indicators such as Price To Sales Ratio of 18.58, Dividend Yield of 0.0 or PTB Ratio of 7.66. Icecure financial statements analysis is a perfect complement when working with Icecure Medical Valuation or Volatility modules.
  
Build AI portfolio with Icecure Stock
Check out the analysis of Icecure Medical Correlation against competitors.
To learn how to invest in Icecure Stock, please use our How to Invest in Icecure Medical guide.
Evaluating Icecure Medical's Net Receivables across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Icecure Medical's fundamental strength.

Latest Icecure Medical's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Icecure Medical over the last few years. It is Icecure Medical's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Icecure Medical's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Icecure Net Receivables Regression Statistics

Arithmetic Mean140,620
Geometric Mean914.92
Coefficient Of Variation143.14
Mean Deviation145,578
Median65,772
Standard Deviation201,284
Sample Variance40.5B
Range771K
R-Value0.56
Mean Square Error29.5B
R-Squared0.32
Significance0.02
Slope22,424
Total Sum of Squares648.2B

Icecure Net Receivables History

2026194.2 K
2025254.2 K
2024221 K
2023103 K
2022366 K
2021771 K
2020165 K

About Icecure Medical Financial Statements

Icecure Medical investors utilize fundamental indicators, such as Net Receivables, to predict how Icecure Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables254.2 K194.2 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Icecure Medical is a strong investment it is important to analyze Icecure Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Icecure Medical's future performance. For an informed investment choice regarding Icecure Stock, refer to the following important reports:
Check out the analysis of Icecure Medical Correlation against competitors.
To learn how to invest in Icecure Stock, please use our How to Invest in Icecure Medical guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Will Health Care Equipment & Supplies sector continue expanding? Could Icecure diversify its offerings? Factors like these will boost the valuation of Icecure Medical. Market participants price Icecure higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Icecure Medical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.25)
Revenue Per Share
0.05
Quarterly Revenue Growth
0.284
Return On Assets
(0.63)
Return On Equity
(1.58)
Understanding Icecure Medical requires distinguishing between market price and book value, where the latter reflects Icecure's accounting equity. The concept of intrinsic value - what Icecure Medical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Icecure Medical's price substantially above or below its fundamental value.
Please note, there is a significant difference between Icecure Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Icecure Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Icecure Medical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.